Search 

focus on CVD, oncology，immunology

healthcare VC

Zhejiang Jianfeng Pharmaceutical Co., Ltd., founded on Dec. 30th, 1998, is a wholly-owned subsidiary of listed company Zhejiang Jianfeng Group Co., Ltd. (SHA: 600668). 　　Our company consists of five industrial enterprises, three commercial enterprises, three scientific institutions and two mobile postdoctoral stations. It is one of National Top 100 Pharmaceutical Enterprises, one of Top 10 Pharmaceutical Industrial Enterprises of Zhejiang Province, National Key High-tech Enterprise, National high-tech Industrialization Demonstration Project Enterprise, Innovative Demonstration Enterprise of Zhejiang Province, and AAA-level Contract-honoring and Promise-keeping Enterprise of Zhejiang Province.

Our key products include Aspartic Acid Amlodipine Tablets, Aceclofenac Sustained-release Tablets, Paroxetine Hydrochloride Tablets, Cefmenoxime Hydrochloride for Injection, Yufeng Ningxin Drop Pills, Penciclovir for Injection, Sodium Hyaluronate Eye Drops, and etc.

Adhering to the corporate spirit of “Aiming for Top One, Producing Fine Medicine”, pursuing business philosophy of “science and technology achieve health”, our company has been oriented by the development of bulk pharmaceutical chemicals with high technology content and high-added value, and new chemical medicine preparations and aided by the natural products extraction and proprietary Chinese medicine preparations. Meanwhile, our company is paying attention to the development method of new biological agent medicine, and will enter into the health product field in good time. We now have a main line with three major series products, which are anti-infection medicine, cardiovascular medicine, and anti-depression medicine. Depending on first-rate business philosophy, first-rate production management and first-rate products, our company will create a famous brand that is trusted by the public, and contribute to the health of human.

ZY Therapeutics Inc. is a venture backed startup company focusing on developing innovative precision drug delivery technology. It was founded by two scientists in 2015 in North Carolina. In 2017, ZY’s leading project won collaboration award from Nanotechnology Characterization Lab (NCL), part of national lab established by FDA, NCI and NIST in a concerted effort to regulate and support nanotechnology in oncology space. ZY’s proprietary delivery platforms currently focus on optimized injectable formulations to deliver oncology therapy to the action sites. The first biodegradable oncology nano-formulation, ZY-010-PNP, completed Pre-IND discussion with the FDA and agreement on 505b(2) regulatory pathway was achieved. Further, the isotope labeling human plasma In vitro study as well as canine pharmacokinetic study conducted by NCL suggest a unique drug releasing profile in comparison to the benchmark brands suggesting enhanced the therapeutic effect with lower safety concern. An IND was filed with favorable responses of communication from FDA were received in 2018 and 2020. The active targeting delivery nanomedicine ZY-012-CNP for prostate cancer is in preclinic development and scheduled to file Pre-IND application in Q2 2021. Additional products are in encapsulation feasibility studies. The target indications cover majority of solid tumors, including but not limited to TNBC, Ovarian Cancer and mCPRC, of which xenograft in vivo models have proved the drug efficacy. On the same platform, additional active drugs with solubility and / or acute toxicity issues were successfully formulated to greatly improve delivery efficacy and safety.
ZY has developed multiple platform technologies and related patents were filed to protect global rights. Additional patents on individual product will be filed to protect the exclusive rights. This layered IP strategy ensures a long patent life for future product.
Located in Research Triangle Park in North Carolina, ZY Therapeutics has an interdisciplinary R&D team and 4,500+ sf lab space right in the heart of the southeast bio-hub. Co-founder and CEO Dr. Jian Bao has 20 years’ experience in pharmaceutical development, from discovery to clinical development. She received PhD from University of Pittsburgh and B.S. from Beijing University, both in Chemistry. Co-founder and CSO Dr. Jun Li has many years of experience in innovative drug delivery system. The core team has a combined decades of pharmaceutical product development experience, with veteran cross-functional team leaders. ZY has assembled an advisor board that consists of world class experts in drug delivery and oncologists from both academia and industry.
ZY Therapeutics is actively seeking funding and collaboration to further develop our platform technologies and promising candidates. We look forward to taking our nano-formulations to clinic in 2021 and beyond.

Laurel Venture Capital is a life science focused venture capital firm with expertise on investment in innovative and breakthrough early stage therapeutics and technologies worldwide.